REgistry-based Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX)
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Multicenter, phase IV, registry-based, randomized controlled trial. Patients starting
long-term oxygen therapy (LTOT) are randomized between LTOT prescribed 24 h/day or 15 h/day
using the Swedish Register for Respiratory Failure (Swedevox). Clinical follow-up and
concurrent treatments are according to routine clinical practice. The main endpoints of
mortality, hospitalizations, and incident disease are assessed using Swedish registry data,
with expected complete follow-up. Patient-reported outcomes are assessed using a posted
questionnaire at 3 and 12 months. The study is managed by the Uppsala Clinical Research
Centre (UCR).